AOD-9604 Research

Ng FM, Sun J, Sharma L, et al.

One of the foundational animal studies establishing AOD-9604’s lipolytic mechanism. Researchers confirmed that the C-terminal fragment of growth hormone specifically activates fat breakdown in adipose tissue without affecting IGF-1 levels or insulin sensitivity — the core design hypothesis of the compound. These results in obese rodent models generated the scientific rationale for advancing to human clinical trials.

Heffernan M, et al.

This study examined AOD-9604’s fat-burning mechanism more deeply in obese mice — including mice without functioning beta-3 adrenergic receptors. The findings confirmed that AOD-9604 reduces fat accumulation and promotes fat oxidation, and that while some of its effects involve beta-3 adrenergic signaling, additional pathways are also involved. The persistence of some effects in knock-out mice suggested a more complex mechanism than initially thought.

Stier H, Vos E, Kenley D

The key human safety study of AOD-9604, reporting findings from trials involving over 900 participants across six studies. AOD-9604 was found to be well tolerated with no significant effects on glucose levels, IGF-1, or other metabolic markers — confirming the selective mechanism designed to avoid growth hormone’s side effects. The clean safety profile remains one of AOD-9604’s genuine strengths even after its weight loss efficacy failed to be demonstrated in the pivotal Phase 2b trial.

Emirati Times — Research Summary

A 2025 analysis examining the full arc of AOD-9604’s development — from promising preclinical data to clinical failure and discontinuation. The article documents how a 24-week Phase 2b trial in 536 subjects found no statistically significant weight loss difference from placebo, leading Metabolic Pharmaceuticals to terminate the obesity development program in 2007. It also covers the FDA’s December 2024 determination that AOD-9604 should not be included on the 503A compounding bulks list, and the pivot toward cartilage repair as an emerging research direction. An important case study in how promising animal data can fail to translate to human clinical outcomes.